Glycopeptide epitope facilitates HIV-1 envelope specific humoral immune responses by eliciting T cell help.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 32439962.
- Also identified by DOI 10.1038/s41467-020-16319-0 and PMC identifier 7242320.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
The inherent molecular complexity of human pathogens requires that mammals evolved an adaptive immune system equipped to handle presentation of non-conventional MHC ligands derived from disease-causing agents, such as HIV-1 envelope (Env) glycoprotein. Here, we report that a CD4<sup>+</sup> T cell repertoire recognizes a glycopeptide epitope on gp120 presented by MHCII pathway. This glycopeptide is strongly immunogenic in eliciting glycan-dependent cellular and humoral immune responses. The glycopeptide specific CD4<sup>+</sup> T cells display a prominent feature of Th2 and Th17 differentiation and exert high efficacy and potency to help Env trimer humoral immune responses. Glycopeptide-induced CD4<sup>+</sup> T cell response prior to Env trimer immunization elicits neutralizing antibody development and production of antibodies facilitating uptake of immunogens by antigen-presenting cells. Our identification of gp120 glycopeptide-induced, T cell-specific immune responses offers a foundation for developing future knowledge-based vaccines that elicit strong and long-lasting protective immune responses against HIV-1 infection.
Medical subject headings
- CD4-Positive T-Lymphocytes
- Epitopes, T-Lymphocyte
- HIV Envelope Protein gp120
- HIV-1
- Immunity, Humoral